Learn
Looking for more information?
Contact our responsive and friendly client services team any time.
Current price
$0.375
▾0.02 (5.63%)
Last trade: 12/12, 4:53PM
Market cap
$545.72m
Market closed
Talk to Immutep Limited directly.
Sign up to their Investor Hub for direct access to the Immutep Limited team, ask them questions, and see personal updates.
Investor Presentations
Principal Activity
Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Address
Level 12/95 Pitt St, Sydney NSW 2000, Australia
Website
News
Announcements
Filter
Announcement | T+2 Movement | Date |
---|---|---|
Market Data
Day
3m
1yr
5yr
Current price
$0.375
Open price
-
Day low-high
-
Price change
Percent change
Previous close
-
Volume
-
Turnover
-
Bid price
-
Ask price
-
Market cap
-
Shares outstanding
-
Year high
-
Year low
-
Year low-high
-
Earnings per share
-
Price/earnings ratio
-
Dividend yield
-
Dividend per share
-
Franking
-
Investor Presentations
News
Sector Peers
Company | Market Cap | ||
---|---|---|---|
Support
Live Chat
Markets